QLS31905 + nab-paclitaxel + gemcitabine

**QLS31905 + nab-paclitaxel + gemcitabine** is a combination regimen under clinical investigation for the treatment of advanced solid tumors, primarily targeting claudin 18.2-positive cancers such as advanced pancreatic cancer. QLS31905 is a bispecific antibody developed to target Claudin18.2 on tumor cells and CD3 on T cells, thereby redirecting T cell cytotoxicity specifically against tumor cells with Claudin18.2 expression. Nab-paclitaxel is a nanoparticle albumin-bound formulation of paclitaxel, a microtubule inhibitor, while gemcitabine is a nucleoside analog that inhibits DNA synthesis. The regimen combines the immune-mediated targeting mechanism of QLS31905 with the cytotoxic effects of standard chemotherapies nab-paclitaxel and gemcitabine.